Top Midday Gainers

MT Newswires Live
Yesterday

Guardant Health (GH) shares soared 26% amid heavy trading after the company reported overnight improved Q3 financial results and lifted its 2025 revenue outlook.

More than 6.4 million shares traded intraday compared with a daily average of about 2.6 million.

Novo Nordisk (NVO) said Thursday it submitted an unsolicited proposal to acquire Metsera (MTSR) for $56.50 per share, for an aggregated equity value of about $6.5 billion or an enterprise value of around $6.0 billion.

In a separate statement, Metsera said Novo Nordisk's proposal constitutes a "superior company proposal" to Pfizer's (PFE) bid, which is valued at $7.3 billion, including milestones.

Metsera shares soared 25% as intraday trading volume advanced to more than 6.7 million from a daily average of about 2.04 million.

Indivior (INDV) reported Q3 adjusted earnings and revenue that grew from a year ago, and the company also raised its 2025 revenue guidance.

Shares jumped 15%, with intraday trading volume at 7.7 million compared with a daily average of about 2.5 million.

Price: 92.34, Change: +20.07, Percent Change: +27.76

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10